Supplementary Figure S3 from Telisotuzumab Adizutecan (ABBV-400), a Novel c-Met–Targeting Antibody–Drug Conjugate: First-in-Human Results in Advanced Gastric/Gastroesophageal Junction Cancer

Authors: John H. Strickler, Judith Raimbourg, Jonathan E. Cohen et al.

Publication:

Published: Unknown date

Source: Crossref

Back to Search View Original Cite This Article

Abstract

<jats:p><p>Supplementary Figure S3. Cycle 1 PK (Cmax and AUC) comparisons for Temab-A conjugate and free Top1 inhibitor following 3-mg/kg Q3W dosing of Temab-A in Asian and non-Asian patients with GEA.</p></jats:p>

Keywords

temaba psupplementary figure cycle cmax

Supplementary Figure S3 from Telisotuzumab Adizutecan (ABBV-400), a Novel c-Met–Targeting Antibody–Drug Conjugate: First-in-Human Results in Advanced Gastric/Gastroesophageal Junction Cancer

Abstract

Keywords

Related Articles

Supplementary Table S8 from HLA Class I Expression Is Associated with Increased Immune Cell Density and PTEN Loss in Prostate Cancer

Supplementary Figure S9 from HLA Class I Expression Is Associated with Increased Immune Cell Density and PTEN Loss in Prostate Cancer

Figure S8 from MPND Loss Epigenetically Activates TGFβ/SMAD3 Signaling to Drive Tumor Progression and Metastasis in Non–Small Cell Lung Cancer

Table S11 from GNAQ Induces Melanomagenesis in Mitfa-Independent Melanocyte Progenitors in a Zebrafish Model of Uveal Melanoma

Table S1 from GNAQ Induces Melanomagenesis in Mitfa-Independent Melanocyte Progenitors in a Zebrafish Model of Uveal Melanoma